Effects of tirzepatide versus insulin glargine on kidney outcomes in type 2 diabetes in the SURPASS-4 trial: post-hoc analysis of an open-label, randomised, phase 3 trial


  • 1.
    • American Diabetes Association

    9. Pharmacological Approaches to Glycemic Management: Standards of Medical Care in Diabetes – 2021.

    diabetes treatment. 2021; 44: S111-S124

  • 2.
    • Cosentino F
    • Grant PJ
    • Aboyans V
    • et al.

    2019 ESC Guidelines on Diabetes, Prediabetes and Cardiovascular Disease developed in collaboration with EASD.

    Your heart J 2020; 41: 255-323

  • 3.
    • Bus JB
    • Wexler DJ
    • Tsapas A
    • et al.

    2019 update to: Management of Hyperglycemia in Type 2 Diabetes, 2018. A consensus report from the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).

    diabetology. 2020; 63: 221-228

  • 4.
    • Sattar N
    • Lee MMY
    • Kristensen SL
    • et al.

    Cardiovascular, mortality, and renal outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomized trials.

    Lancet Diabetes Endocrinol. 2021; 9: 653-662

  • 5.
    • van der Aart-van der Beek AB
    • Clegg LE
    • Penland RC
    • et al.

    The effect of exenatide once weekly on the estimated slope of glomerular filtration rate depends on baseline renal risk: a post hoc analysis of the EXSCEL study.

    diabetes obesity metab. 2020; 22: 2493-2498

  • 6.
    • Shaman AM
    • Bain SC
    • Bakris GL
    • et al.

    Effect of glucagon-like peptide-1 receptor agonists semaglutide and liraglutide on renal outcomes in patients with type 2 diabetes: pooled analysis of SUSTAIN 6 and LEADER.

    Traffic. 2022; 145: 575-585

  • 7.
    • Tuttle KR
    • Rayner B
    • Lakshmanan MC
    • et al.

    Clinical outcomes by albuminuria status with dulaglutide versus insulin glargine in participants with diabetes and CKD: Exploratory Analysis of AWARD-7.

    kidney360. 2020; 2: 254-262

  • 8th.
    • Moller CL
    • Visitor D
    • Faerch K
    • et al.

    Glucose-dependent insulinotropic polypeptide is associated with lower low-density lipoprotein but unhealthy fat distribution independent of insulin: the ADDITION-PRO study.

    J Clin Endocrinol Metab. 2016; 101: 485-493

  • 9.
    • Frias JP
    • Nauck MA
    • Van J
    • et al.

    Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a phase 2 randomized, placebo-controlled and active comparative study.

    Lancet. 2018; 392: 2180-2193

  • 10
    • RosenstockJ
    • Wysham C
    • Frias JP
    • et al.

    Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomized phase 3 study.

    Also Read :  Exclusive: Google faces EU antitrust charges over its adtech business - sources

    Lancet. 2021; 398: 143-155

  • 11.
    • Frias JP
    • Davies MJ
    • RosenstockJ
    • et al.

    Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes.

    N Engl. J Med. 2021; 385: 503-515

  • 12.
    • Ludwig B
    • Giorgino F
    • Jodar E
    • et al.

    Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a phase 3, randomized, open-label, parallel-group study.

    Lancet. 2021; 398: 583-598

  • 13.
    • dahl d
    • Onishi Y
    • Norwood P
    • et al.

    Effect of subcutaneous tirzepatide compared to placebo added to titrated insulin glargine on glycemic control in patients with type 2 diabetes: the randomized clinical trial SURPASS-5.

    JAMA. 2022; 327: 534-545

  • 14
    • Del Prato S
    • Kahn SE
    • Pavo I
    • et al.

    Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomized, open-label, parallel-group, multicenter, phase 3 study.

    Lancet. 2021; 398: 1811-1824

  • fifteen.
    • Wilson JM
    • Nikooienejad A
    • Robin’s DA
    • et al.

    The dual glucose-dependent insulinotropic peptide and glucagon-like peptide-1 receptor agonist tirzepatide improves lipoprotein biomarkers associated with insulin resistance and cardiovascular risk in patients with type 2 diabetes.

    diabetes obesity metab. 2020; 22: 2451-2459

  • 16
    • Sattar N
    • McGuire DK
    • Pavo I
    • et al.

    Tirzepatide risk assessment for cardiovascular events: a pre-specified meta-analysis.

    Nat Med. 2022; 28: 591-598

  • 17
    • Riddle MC
    • RosenstockJ
    • court j

    The Treat-to-Target study: randomized addition of glargine or NPH human insulin to the oral therapy of patients with type 2 diabetes.

    diabetes treatment. 2003; 26: 3080-3086

  • 18
    • Levey AS
    • Stevens LA
    • Schmid CH
    • et al.

    A new equation for estimating glomerular filtration rate.

    Ann Intern Med. 2009; 150: 604-612

  • 19
    • Wilson JM
    • Lin Y
    • Luo MJ
    • et al.

    The dual glucose-dependent insulinotropic polypeptide and the glucagon-like peptide-1 receptor agonist tirzepatide improve cardiovascular risk biomarkers in patients with type 2 diabetes: a post hoc analysis.

    diabetes obesity metab. 2022; 24: 148-153

  • 20
    • Inker LA
    • Heerpink HJL
    • Tighouart H
    • et al.

    GFR increase as a surrogate endpoint for renal disease progression in clinical trials: a meta-analysis of treatment effects of randomized controlled trials.

    J.Am. society nephrol. 2019; 30: 1735-1745

  • 21
    • Oshima M
    • Nele B
    • Toyama T
    • et al.

    Different eGFR decline thresholds and renal effects of canagliflozin: data from the CANVAS program.

    Also Read :  Dow Jones Falls As Netflix Soars On Earnings; Tesla Earnings Next

    J.Am. society nephrol. 2020; 31: 2446-2456

  • 22
    • Cherney DZI
    • Cosentino F
    • Dagogo-Jack S
    • et al.

    Ertugliflozin and slope of chronic eGFR.

    Clin J Am Soc Nephrol. 2021; 16: 1345-1354

  • 23
    • Holtkamp FA
    • de Zeeuw D
    • Thomas MC
    • et al.

    An acute drop in estimated glomerular filtration rate during treatment with losartan predicts a slower decline in long-term renal function.

    kidney internal 2011; 80: 282-287

  • 24
    • Oshima M
    • Jardine MJ
    • Agarwal R
    • et al.

    Findings from the CREDENCE study indicate an acute drop in estimated glomerular filtration rate during canagliflozin treatment with implications for clinical practice.

    kidney internal 2021; 99: 999-1009

  • 25
    • Tonnejck L
    • Muskete MH
    • Smith’s MM
    • et al.

    Glomerular hyperfiltration in diabetes: mechanisms, clinical significance and treatment.

    J.Am. society nephrol. 2017; 28: 1023-1039

  • 26
    • Crajoinas RO
    • Orichio FT
    • Pessoa TD
    • et al.

    Mechanisms mediating the diuretic and natriuretic effects of the incretin hormone glucagon-like peptide-1.

    Am J Physiol Renal Physiol. 2011; 301: F355-F363

  • 27
    • Heerpink HJL
    • Greene T
    • Tighouart H
    • et al.

    Change in albuminuria as a surrogate endpoint for renal disease progression: a meta-analysis of treatment effects in randomized clinical trials.

    Lancet Diabetes Endocrinol. 2019; 7: 128-139

  • 28
    • de Bur IH
    • Caramori ML
    • Chan JCN
    • et al.

    KDIGO 2020 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease.

    kidney internal 2020; 98: S1-115

  • 29
    • Oshima M
    • New BL
    • Li J
    • et al.

    Early change in albuminuria with canagliflozin predicts renal and cardiovascular outcomes: a post hoc analysis from the CREDENCE study.

    J.Am. society nephrol. 2020; 31: 2925-2936

  • 30
    • finan b
    • Mueller TD
    • Clemensen C
    • Perez-Tilve D
    • DiMarchi RD
    • Chop MH

    Reappraisal of GIP pharmacology for metabolic diseases.

    Trends Mol Med. 2016; 22: 359-376

  • 31
    • Hammoud SH
    • Al Zaim I
    • Al-Dhaheri Y
    • Oath AH
    • El-Yazbi AF

    Inflammation of perinephric adipose tissue: new evidence linking metabolic dysfunction to renal disease.

    Front Endocrinol (Lausanne). 2021; 12707126

  • 32
    • Muskiet MHA
    • Tonnejck L
    • Smith’s MM
    • et al.

    GLP-1 and the kidney: from physiology to pharmacology and outcomes in diabetes.

    Nat Rev Nephrol. 2017; 13: 605-628

  • 33
    • Alice RZ
    • Cox EJ
    • Neumiller JJ
    • Tuttle KR

    Incretin drugs in diabetic kidney disease: biological mechanisms and clinical evidence.

    Also Read :  He wrote for a president. What Cody Keenan can teach you about crafting a great speech

    Nat Rev Nephrol. 2021; 17: 227-244

  • 34
    • Gerstein HC
    • Colhoun HM
    • Dagenais GR
    • et al.

    Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the randomized, placebo-controlled REWIND study.

    Lancet. 2019; 394: 131-138

  • 35
    • Gerstein HC
    • Sattar N
    • RosenstockJ
    • et al.

    Cardiovascular and renal outcomes with efpeglenatide in type 2 diabetes.

    N Engl. J Med. 2021; 385: 896-907

  • 36
    • man JFE
    • Ørsted DD
    • Brown-Frandsen K
    • et al.

    Liraglutide and renal outcomes in type 2 diabetes.

    N Engl. J Med. 2017; 377: 839-848

  • 37
    • Heerpink HJL
    • Parving HH
    • Address DL
    • et al.

    Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomized, placebo-controlled study.

    Lancet. 2019; 393: 1937-1947

  • 38
    • Perkovic V
    • Jardine MJ
    • Nele B
    • et al.

    Canagliflozin and renal outcomes in type 2 diabetes and nephropathy.

    N Engl. J Med. 2019; 380: 2295-2306

  • 39
    • Heerpink HJL
    • Stefansson B.V
    • Correa-Rotter R
    • et al.

    Dapagliflozin in patients with chronic kidney disease.

    N Engl. J Med. 2020; 383: 1436-1446

  • 40
    • de Zeeuw D
    • Coll. B
    • Address D
    • et al.

    The endothelin antagonist atrasentan reduces residual albuminuria in patients with type 2 diabetic nephropathy.

    J.Am. society nephrol. 2014; 25: 1083-1093

  • 41
    • Pollock C
    • Stefansson B
    • Reyner D
    • et al.

    Albuminuria-lowering effects of dapagliflozin alone and in combination with saxagliptin and effects of dapagliflozin and saxagliptin on glycemic control in patients with type 2 diabetes and chronic kidney disease (DELIGHT): a randomized, double-blind, placebo-controlled study.

    Lancet Diabetes Endocrinol. 2019; 7: 429-441

  • 42
    • Yale JF
    • Bakris G
    • Cariou B
    • et al.

    Efficacy and safety of canagliflozin in patients with type 2 diabetes and chronic kidney disease.

    diabetes obesity metab. 2013; fifteen: 463-473

  • 43
    • Davies MJ
    • Bain SC
    • Atkin SL
    • et al.

    Efficacy and safety of liraglutide compared to placebo as add-on therapy to glucose-lowering therapy in patients with type 2 diabetes and moderate renal impairment (LIRA-RENAL): a randomized clinical trial.

    diabetes treatment. 2016; 39: 222-230

  • 44
    • Gilbert RE
    • man JFE
    • Hanefeld M
    • et al.

    Basal insulin glargine and microvascular outcomes in subjects with dysglycemia: results from the Outcome Reduction with an Initial Glargine Intervention (ORIGIN) study.

    diabetology. 2014; 57: 1325-1331



  • Source link